Netupitant And Palonosetron has 18 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Rifampin, Alprazolam, Anticoagulants (General Class). Patients taking Netupitant And Palonosetron should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 18
- Major
- 1
- Moderate
- 16
Major (1)
- Netupitant And Palonosetron + Rifampin— CYP3A4 inducer decreases plasma concentrations of netupitant; avoid concomitant use.
Moderate (16)
- Netupitant And Palonosetron + Alprazolam— Benzodiazepine metabolized via CYP3A4; increased plasma concentrations possible when administered with AKYNZEO.
- Netupitant And Palonosetron + Anticoagulants (General Class)— Netupitant inhibits CYP3A4 for 6 days, increasing plasma concentrations of CYP3A4 substrates. Avoid concomitant use for …
- Netupitant And Palonosetron + Cyclophosphamide— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Netupitant And Palonosetron + Dexamethasone— Netupitant increases systemic exposure of dexamethasone more than 2-fold on Days 2 and 4; administer reduced dose of dex…
- Netupitant And Palonosetron + Docetaxel— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Netupitant And Palonosetron + Etoposide— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Netupitant And Palonosetron + Ifosfamide— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Netupitant And Palonosetron + Imatinib— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Netupitant And Palonosetron + Irinotecan— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Netupitant And Palonosetron + Midazolam— Netupitant significantly increases systemic exposure to midazolam; consider potential effects of increased plasma concen…
- Netupitant And Palonosetron + Paclitaxel— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Netupitant And Palonosetron + Triazolam— Benzodiazepine metabolized via CYP3A4; increased plasma concentrations possible when administered with AKYNZEO.
- Netupitant And Palonosetron + Vinblastine— Netupitant inhibits CYP3A4, increasing plasma concentrations of concomitant CYP3A4 substrates for 6 days; avoid concomit…
- Netupitant And Palonosetron + Vincristine— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Netupitant And Palonosetron + Vinorelbine— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
- Netupitant And Palonosetron + Warfarin— Monitor INR and adjust warfarin dosage as needed with concomitant use of AKYNZEO to maintain target INR range.